Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Alkem1/Cya
Common Name:
Alk-KO
Product ID:
S-KO-17058
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Alk-KO
Strain ID
KOCMP-11682-Alk-B6J-VA
Gene Name
Alk
Product ID
S-KO-17058
Gene Alias
CD246; Tcrz
Background
C57BL/6JCya
NCBI ID
11682
Modification
Conventional knockout
Chromosome
17
Phenotype
MGI:103305
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Alkem1/Cya mice (Catalog S-KO-17058) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000086639
NCBI RefSeq
NM_007439
Target Region
Exon 4
Size of Effective Region
~1.1 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase. It plays a crucial role in various biological processes, and its abnormal activation can lead to oncogenesis. Different ALK gene alterations, such as point mutations, deletions, and rearrangements, have been identified across a range of tumour types [2]. These alterations can disrupt normal cellular signalling pathways, making ALK an important target for cancer research [2].

ALK rearrangements are oncogenic drivers in several malignancies, most notably in 3-7% of advanced non-small cell lung cancer (NSCLC) [3,5]. In NSCLC, the EML4-ALK fusion is the most prevalent, with different EML4-ALK variants showing differential responses to ALK tyrosine kinase inhibitors (TKIs) [2,7]. In neuroblastoma, ALK is an oncogenic driver, and ALK inhibitors can increase ALK expression, sensitizing cells to ALK.CAR-T cells [1]. Resistance to ALK inhibitors, both on-target and off-target, is a significant issue. For example, different ALK inhibitors are associated with distinct spectra of ALK resistance mutations, and sequential use of inhibitors can lead to the emergence of compound ALK mutations that confer resistance to drugs like lorlatinib [4,6].

In conclusion, ALK is a key molecule in cancer biology, especially in NSCLC and neuroblastoma. Research on ALK, including studies using genetic models (although not specifically KO/CKO mouse models in the provided references), has led to the development of ALK-targeted drugs. Understanding ALK's role in tumour biology and resistance mechanisms to its inhibitors is crucial for optimizing therapeutic strategies for ALK-positive diseases.

References:

1. Bergaggio, Elisa, Tai, Wei-Tien, Aroldi, Andrea, Dotti, Gianpietro, Chiarle, Roberto. 2023. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. In Cancer cell, 41, 2100-2116.e10. doi:10.1016/j.ccell.2023.11.004. https://pubmed.ncbi.nlm.nih.gov/38039964/

2. Hallberg, B, Palmer, R H. . The role of the ALK receptor in cancer biology. In Annals of oncology : official journal of the European Society for Medical Oncology, 27 Suppl 3, iii4-iii15. doi:10.1093/annonc/mdw301. https://pubmed.ncbi.nlm.nih.gov/27573755/

3. Poei, Darin, Ali, Sana, Ye, Shirley, Hsu, Robert. 2024. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. In Cancer drug resistance (Alhambra, Calif.), 7, 20. doi:10.20517/cdr.2024.25. https://pubmed.ncbi.nlm.nih.gov/38835344/

4. Gainor, Justin F, Dardaei, Leila, Yoda, Satoshi, Engelman, Jeffrey A, Shaw, Alice T. 2016. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. In Cancer discovery, 6, 1118-1133. doi:. https://pubmed.ncbi.nlm.nih.gov/27432227/

5. Desai, Aakash, Lovly, Christine M. 2023. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. In Translational lung cancer research, 12, 615-628. doi:10.21037/tlcr-22-708. https://pubmed.ncbi.nlm.nih.gov/37057106/

6. Yoda, Satoshi, Lin, Jessica J, Lawrence, Michael S, Hata, Aaron N, Shaw, Alice T. 2018. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. In Cancer discovery, 8, 714-729. doi:10.1158/2159-8290.CD-17-1256. https://pubmed.ncbi.nlm.nih.gov/29650534/

7. Zhang, Shannon S, Nagasaka, Misako, Zhu, Viola W, Ou, Sai-Hong Ignatius. 2021. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. In Lung cancer (Amsterdam, Netherlands), 158, 126-136. doi:10.1016/j.lungcan.2021.06.012. https://pubmed.ncbi.nlm.nih.gov/34175504/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest